MILL LAB

MAMMALIAN CILIA DIVERSITY

  • Home
  • PUBLICATIONS
  • MEMBERS
    • MILL LAB
    • PAST MEMBERS
    • The PI
    • Current Members
    • Mill lab flashbacks
  • PRE-PRINTS
  • NEWS
  • Opportunities
    • Join us?
    • CILIA_AI PHD Position
  • OUTREACH
    • PCD Family Day 2019
    • PCD Awareness Day 2018 Overview
    • PCD Awareness Day Schedule
  • Media
    • Genome Editing for PCD- BBC Alba Segment 15/11/2019
    • BSCB WICB Medal talk 2019
    • FEBSNews Article: Lessons from Lockdown: Moving Meetings Online
  • Cilia Meetings
    • Cilia Meetings
    • Past Cilia Events 2020
    • Past Cilia Events 2021
    • Past Cilia Events 2022
    • Past Cilia Events 2023
    • Past Cilia Events 2024
    • Past Cilia Events 2025
  • CONTACT US

How RPGR sets the rhythm of actin dynamics at the connecting cilium during photoreceptor disc formation

November 23, 2022 by Pleasantine Mill

Led by our amazing clinician scientist Roly Megaw, we are excited to share our latest paper on BioRXiv: ‘Ciliary tip actin dynamics regulate the cadence of photoreceptor disc formation.’ This was the result of great collaborations with Wensel lab (BCM Houston, US) and Machesky lab (Beatson Institute, UK), where we used in vivo cryo-electron tomography, advanced live imaging, novel reporter mice and humanised mouse models to show how photoreceptor discs are formed and why patients lose their sight when this goes wrong.

In a remarkable biological feat, photoreceptors regrow their outer segments every week, to ensure normal vision. Our sub-tomogram averaging studies definitively show that actin filaments extend into newly forming discs to regulate this process. RPGR mutations cause inherited retinal dystrophies; the leading cause of visual loss in children and working adults. We show RPGR regulates the disassembly of these actin filaments where discs form and patient mutations prevent this, leading to reduced actin disassembly.

As a result, discs cannot form and are instead shed as extracellular vesicles, causing photoreceptor death and sight loss. Excitingly, pharmacological targeting of the actin skeleton can reduce the number of shed vesicles. This study, funded by Wellcome, sheds real light on a fundamental biological process and, perhaps more importantly, an untreatable disease. Further work will determine if this could be developed into a realistic therapeutic strategy.

November 23, 2022 /Pleasantine Mill
  • Newer
  • Older